StockNow
Calendar
Log in
U.S. Markets

Johnson & Johnson (JNJ) says 2-year ICOTYDE data in moderate-to-severe plaque psoriasis showed sustained efficacy through week 112

StockNow breaking-news AI analysis

Johnson & Johnson reported sustained ICOTYDE efficacy through week 112, but the supplied headline contains no numerical efficacy, trial, or safety details.

1 stocks
JNJJohnson & Johnson$256.13Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

A US military source told Al-Hadath that "US forces received orders to mobilise last Sunday"; "We have replaced thousands of missiles and sent our forces the ammunition they need"

Geopolitics

"[Yemen] Government forces complete control over Bab al-Mandab after clearing it", Al Hadath reports citing sources

Geopolitics

IRGC Navy political affairs officer says vessels violating restrictions in the Strait of Hormuz are punished every night, via Arabic TV